Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2005

01-02-2005 | Concise Article

Long-term survival and interruption of HAART in HIV-related pulmonary hypertension

Authors: A. S. Zinkernagel, J. von Overbeck, M. Opravil, R. Jenni, R. Speich, N. J. Mueller

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2005

Login to get access

Abstract

Reported here is a case of a patient with pulmonary arterial hypertension related to HIV (PAHRH) in which lipodystrophy necessitated interruption of highly active antiretroviral therapy (HAART) and long-term survival was the outcome. Although previous studies have suggested antiretroviral therapy may benefit patients with this rare complication of HIV infection, no worsening of PAHRH was observed when HAART was interrupted. Clinical and echocardiographic parameters remained stable during 7 months of follow up. In cases in which HAART is associated with relevant toxicity, interruption of HAART in patients with PAHRH can be considered, but should be used only if no alternatives are available. Close follow-up is warranted.
Literature
1.
go back to reference Speich R, Jenni R, Opravil M, Pfab M, Russi EW (1991) Primary pulmonary hypertension in HIV infection. Chest 100:1268–1271 Speich R, Jenni R, Opravil M, Pfab M, Russi EW (1991) Primary pulmonary hypertension in HIV infection. Chest 100:1268–1271
2.
go back to reference Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Luthy R (1997) HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155:990–995 Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Luthy R (1997) HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155:990–995
3.
go back to reference Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA (2000) HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118:1133–1141 Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA (2000) HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118:1133–1141
4.
go back to reference Pellicellii AM, D’Ambrosio C, Vizza CD, Borgia MC, Tanzi P, Pino P, Zachara E, Soccorsi F (2004) HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. Acta Cardiol 59:323–330 Pellicellii AM, D’Ambrosio C, Vizza CD, Borgia MC, Tanzi P, Pino P, Zachara E, Soccorsi F (2004) HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. Acta Cardiol 59:323–330
5.
go back to reference Klings ES, Farber HW (2003) The pathogenesis of HIV-associated pulmonary hypertension. Adv Cardiol 40:71–82 Klings ES, Farber HW (2003) The pathogenesis of HIV-associated pulmonary hypertension. Adv Cardiol 40:71–82
6.
go back to reference Cool CD, Rai PR, Yeager ME, Hernandez-Saavedra D, Serls AE, Bull TM, Geraci MW, Brown KK, Routes JM, Tuder RM, Voelkel NF (2003) Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349:1113–1122 Cool CD, Rai PR, Yeager ME, Hernandez-Saavedra D, Serls AE, Bull TM, Geraci MW, Brown KK, Routes JM, Tuder RM, Voelkel NF (2003) Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 349:1113–1122
7.
go back to reference Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A (2003) Long-time survival with HIV-related pulmonary arterial hypertension: a case report. Aids 17:1714–1715 Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A (2003) Long-time survival with HIV-related pulmonary arterial hypertension: a case report. Aids 17:1714–1715
8.
go back to reference Ricciardi MJ, Rubenfire M (1999) How to manage primary pulmonary hypertension. Giving hope to patients with a life-threatening illness. Postgrad Med 105:45–48, 51–46 Ricciardi MJ, Rubenfire M (1999) How to manage primary pulmonary hypertension. Giving hope to patients with a life-threatening illness. Postgrad Med 105:45–48, 51–46
9.
go back to reference Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G (2004) Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170:1212–1217 Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G (2004) Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170:1212–1217
10.
go back to reference Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, Speich R, Opravil M (2004) Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 38:1178–1185 Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, Speich R, Opravil M (2004) Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 38:1178–1185
Metadata
Title
Long-term survival and interruption of HAART in HIV-related pulmonary hypertension
Authors
A. S. Zinkernagel
J. von Overbeck
M. Opravil
R. Jenni
R. Speich
N. J. Mueller
Publication date
01-02-2005
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-005-1289-7

Other articles of this Issue 2/2005

European Journal of Clinical Microbiology & Infectious Diseases 2/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.